Inhibikase Therapeutics Inc (IKT) earnings · $215.2M cap
These earnings events as JSON? API free 100/dayInhibikase Therapeutics Inc (IKT) is a biotechnology company listed on US.
This IKT earnings page is the cached print — revenue, income, and the latest exhibit — not a live call transcript.
Latest reported IKT revenue for 2026-06-30 was $0. Net income was -$19.6M. IKT currently screens at market cap $215.2M.
When the next IKT 8-K Item 2.02 lands, this page should move. Until then the SEC archive is the source.
Period-over-period revenue change is not in cache for IKT. We will not invent a beat or miss.
Not investment advice. Full IKT research stays on the stock page; the tape stays on the quote page.
IKT earnings FAQ
What is IKT's latest net income?
Latest cached Inhibikase Therapeutics Inc (IKT) net income was -$19.6M. Statements: https://lician.com/financials/ikt
What is IKT's latest diluted EPS?
Latest cached Inhibikase Therapeutics Inc (IKT) diluted EPS for Jun 30, 2026 was -$0.11.
What period does the latest IKT earnings print cover?
The latest cached Inhibikase Therapeutics Inc (IKT) earnings print covers Jun 30, 2026. The prior cached period on this page is Mar 31, 2026.
Where are IKT earnings listed?
Cached earnings facts for Inhibikase Therapeutics Inc (IKT) are listed at https://lician.com/earnings/ikt. Statements: https://lician.com/financials/ikt
Not investment advice.